Prospective Study of the Impact of Systemic Corticosteroid Use on Measures of Sleep Disordered Breathing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01228695
Recruitment Status : Completed
First Posted : October 26, 2010
Last Update Posted : October 26, 2010
Israeli association for lung disease
Information provided by:
Rambam Health Care Campus

Brief Summary:

Weight gain is both a significant risk factor for obstructive sleep apnea and a side-effect of long-term systemic steroids therapy.

This study aimed to investigate the impact of long-term systemic steroid treatment on sleep apnea.

Condition or disease Intervention/treatment
Sleep Apnea Other: sleep study

Study Type : Observational
Enrollment : 20 participants
Observational Model: Case-Only
Time Perspective: Prospective
Study Start Date : January 2007
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Group/Cohort Intervention/treatment
steroid treatment Other: sleep study
The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
Other Name: no other names

Primary Outcome Measures :
  1. apnea-hypopnea index [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. sleep study variables [ Time Frame: 3 months ]
    apnea-hypopnea interval desaturation at the end of apnea interval snoring intensity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients scheduled for long-term treatment with oral prednisone (> 10 mg/d for 3 months or more)

Inclusion Criteria:

  • For inclusion, a scheduled therapy with a minimum daily dose of 10 mg prednisone (or equivalent) for at least 3 months was required

Exclusion Criteria:

  • Patients younger than 18 years and those with known sleep apnea or other forms of sleep-disordered breathing were excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01228695

Rambam health care campus
Haifa, Israel, 31096
Sponsors and Collaborators
Rambam Health Care Campus
Israeli association for lung disease

Responsible Party: Israeli association for lung disease Identifier: NCT01228695     History of Changes
Other Study ID Numbers: IRB2421CTIL
First Posted: October 26, 2010    Key Record Dates
Last Update Posted: October 26, 2010
Last Verified: February 2010

Keywords provided by Rambam Health Care Campus:
patients treated with systemic steroids